The contractor shall utilize nanoparticles to deliver the mper-based immunogens to elicit bnabs against the mper of HIV-1 GP41 to develop a protective vaccine against the virus.

Ended Definitive Contract Awarded Last action

Contract number
75N93021C00026
Awardee
Awarding agency
Obligated
$300,000

Award facts

Contract value 100% obligated
$300,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Ames, IA 50014, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00012 $0
Other Administrative Action P00011 $0
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 · Nanovaccine for eliciting 10E8-like bnabs against HIV-1 $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $300,000
Show all 13

About this award

This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small Business Innovation Research (SBIR) program, which has a total small business set-aside designation. Neovaxsyn Inc. conducts infectious disease research and development, including work on HIV/AIDS vaccines, and has received prior federal contracts and grants from NIAID and other Department of Health and Human Services agencies.

Quick answers

Who was awarded contract 75N93021C00026?

75N93021C00026 was awarded to Neovaxsyn Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2021.

How much is contract 75N93021C00026 worth?

The government has obligated $300,000 on 75N93021C00026.

Was contract 75N93021C00026 competed?

The extent of competition for 75N93021C00026 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award